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Globally  there  are  an estimated  3–5  million  cases  of severe  inﬂuenza  illness  every  year,  resulting  in
250,000–500,000  deaths.  At  the  World  Health  Assembly  in  2003,  World  Health  Organization  (WHO)
resolved  to increase  inﬂuenza  vaccine  coverage  rates  (VCR)  for high-risk  groups,  particularly  focusing
on  at  least  75% of  the  elderly  by 2010.  But  systematic  worldwide  data  have  not been  available  to assist
public  health  authorities  to monitor  vaccine  uptake  and  review  progress  toward  vaccination  coverage  tar-
gets.  In  2008,  the  International  Federation  of  Pharmaceutical  Manufacturers  and  Associations  Inﬂuenza
Vaccine  Supply  task  force  (IFPMA  IVS)  developed  a  survey  methodology  to assess  global  inﬂuenza  vac-
cine  dose  distribution.  The  current  survey  results  represent  2011  data  and  demonstrate  the evolution  of
the  absolute  number  distributed  between  2004  and  2011  inclusive,  and  the  evolution  in the  per  capita
doses  distributed  in 2008–2011.  Global  distribution  of  IFPMA  IVS  member  doses  increased  approxi-
mately  86.9%  between  2004  and  2011,  but only  approximately  12.1%  between  2008  and  2011.  The WHO’s
regions  in Eastern  Mediterranean  (EMRO),  Southeast  Asian  (SEARO)  and  Africa (AFRO)  together  account
for  about  47%  of the  global  population,  but only  3.7%  of  all IFPMA  IVS doses  distributed.  While  distributed
doses  have  globally  increased,  they  have  decreased  in EURO  and  EMRO  since  2009.  Dose  distribution
can  provide  a reasonable  proxy  of  vaccine  utilization.  Based  on  the  dose  distribution,  we  conclude  that
seasonal  inﬂuenza  VCR  in many  countries  remains  well  below  the  WHA’s  VCR  targets  and  below  the
recommendations  of  the Council  of the  European  Union  in EURO.  Inter-  and  intra-regional  disparities
in  dose  distribution  trends  call into  question  the  impact  of  current  vaccine  recommendations  at  achiev-
ing  coverage  targets.  Additional  policy  measures,  particularly  those  that  inﬂuence  patients  adherence  to
vaccination  programs,  such  as  reimbursement,  healthcare  provider  knowledge,  attitudes,  practices,  and
communications,  are  required  for VCR  targets  to be met  and  beneﬁt  public  health.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Inﬂuenza is an important cause of morbidity and mortality
lobally, resulting in an estimated 3–5 million cases of severe
nﬂuenza illness and 250,000–500,000 annual deaths worldwide
1]. The annual attack rate with inﬂuenza viruses is 5–10% in adults
nd 20–30% in children [2]. Groups at particular risk of severe
∗ Corresponding author. Tel.: +31 6 512 90531.
E-mail  addresses: bram.palache@abbott.com, bram.palache@ﬂupal.nl
A. Palache), VOriolM@its.jnj.com (V. Oriol-Mathieu),
tika.Abelin@sanoﬁpasteur.com (A. Abelin), t.music@ifpma.org (T. Music).
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.012
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uninﬂuenza infections include pregnant women, children aged <5
years, the elderly (≥65 years), and individuals with underlying non-
communicable health conditions such as heart disease, asthma and
diabetes. Most inﬂuenza deaths occur in adults over 65 years of age.
Vaccination is currently the most effective means of preven-
ting inﬂuenza infection. Currently licensed inﬂuenza vaccines are
safe and efﬁcacious and prevent signiﬁcant annual morbidity
and mortality [2]. Recommended target populations for inﬂuenza
vaccination programs include pregnant women, children aged
6–59 months, the elderly, individuals with speciﬁc chronic non-
communicable diseases, and health-care workers [2]. In 2003,
a World Health Assembly (WHA) resolution set a target calling
for an increase in inﬂuenza vaccine coverage rates (VCR) for all
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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eople at high risk and at least 50% of the elderly by 2006, and
5% by 2010 [3]. Since then, the Council of the European Union
as recommended that member states achieve VCR of 75% in the
lderly and other risk groups and improve the vaccination cov-
rage in health care workers by the 2014–2015 inﬂuenza season
4].
With clear national and supranational recommendations for
accination, countries would be expected to achieve the recom-
ended 75% vaccination coverage target. Yet inﬂuenza vaccination
overage remains below recommended levels in many countries. In
urope, inﬂuenza vaccination is recommended for about 36% of the
opulation or approximately 180 million persons. Yet only about
0 million persons (44% of the population for whom vaccination
s recommended) are estimated to receive vaccine annually [5]. In
he US, inﬂuenza vaccination coverage in all age groups combined
as 41.8% in 2011–2012 [6].
Systematic worldwide data on inﬂuenza VCR are not available
o assist public health authorities to monitor vaccine uptake, and
eview progress toward vaccination coverage targets. Therefore, in
008, the International Federation of Pharmaceutical Manufactur-
rs and Associations Inﬂuenza Vaccine Supply task force (IFPMA
VS) developed a survey methodology to assess inﬂuenza vaccine
ose distribution globally [7]. The survey requested information
rom its members on the supply of seasonal trivalent inﬂuenza
accine doses to all WHO  Member States. The supply period was
eﬁned by calendar year rather than inﬂuenza season to ensure that
oth Northern and Southern inﬂuenza seasons were captured. To
nsure compliance with competition regulations, the survey results
ere collected and aggregated by an independent third-party legal
ounsel.
Global distribution of vaccines can be used as a proxy for vac-
ination coverage, survey results on dose distribution of inﬂuenza
accines in 141 countries for 2004 to 2007 were reported in 2008
7]. Updated and expanded results for 157 countries between 2004
nd 2009 were reported in 2011 [8]. The aim of this paper is to
pdate the results of the previous surveys and to show the evolu-
ion of the absolute number of inﬂuenza vaccine doses distributed
etween 2004 and 2011 inclusive, and the evolution in the per
apita doses distributed between 2008 and 2011.
. Methods
.1. Vaccine dose distribution survey
Member companies of the IFPMA IVS (Abbott Biologicals, Baxter,
iken, Crucell, bioCSL, Denka Seiken, GlaxoSmithKline Biologicals,
reen Cross, Kaketsuken, Kitasato Institute, MedImmune, Novar-
is Vaccines, sanoﬁ pasteur, Sanoﬁ Pasteur MSD  and Sinovac),
hich collectively manufacture and supply the vast majority of the
orld’s seasonal and pandemic inﬂuenza vaccines, were requested
o provide information on the supply of seasonal trivalent inﬂuenza
accine doses to all WHO  Member States during 2010 and 2011. To
nsure compliance with anti-trust regulations, the survey results
ere conﬁdentially collected and aggregated by the IFPMA Secre-
ariat. The resulting anonymized database was then combined with
he results of the previous IFPMA IVS survey (2004–2009) [4], which
ad been compiled using a similar methodology.
.2. Vaccine dose distribution in absolute numbers between 2004
nd  2011Doses distributed by country and by year were aggregated and
hen, to facilitate comparisons, were categorized by distribution to
HO  region.2 (2014) 6369–6376
2.3. Vaccine dose distribution per population size between 2008
and  2011
To  assess vaccine dose distribution in relation to each coun-
try’s population size, the study utilized population data from the
United Nations’ (UN) statistics database [9]. Doses distributed to
each country were expressed per 1000 population in 2008 and
per 1000 population 2011 using the corresponding population ﬁg-
ures from the United Nations’ (UN) statistics database. To facilitate
comparisons, countries were then categorized by WHO  region.
T-test comparisons were performed between rates of dose distri-
bution/1000 population in 2008 and 2011 by WHO  region.
2.4.  Vaccination uptake factors
To better understand the factors inﬂuencing seasonal inﬂuenza
vaccine dose distribution since the previous survey, countries were
categorized into: previously low distribution (<159 doses per 1000
population, in 2008); and, previously high distribution (≥159 doses
per 1000 population, in 2008). This “hurdle” rate of 159 doses per
1000 population was  previously deﬁned as the number of doses
required to vaccinate those aged 65 years or older in more devel-
oped nations [8], and was  again utilized to enable comparisons with
previous reports.
Countries with the greatest proportional increases in per capita
dose distribution between 2008 and 2011 were compared to
those countries with the greatest proportional decreases for the
same period. This excludes 2009 and 2010 data due to the H1N1
inﬂuenza pandemic vaccine distribution. To compare a similar
number of countries with increases and decreases in dose distribu-
tion, 18 countries with the greatest rate of change were compared.
Countries with the greatest proportional increase were selected
according to the hurdle rate: 9 countries below and 9 countries
above the hurdle rate in 2008. Countries with the greatest propor-
tional decrease were selected in the same way.
3. Findings
3.1. Absolute number of IFPMA IVS doses distributed between
2004  and 2011
The  total numbers of IFPMA IVS doses of seasonal inﬂuenza vac-
cine distributed has risen from approximately 262 million in 2004
to about 489 million in 2011, an 87% increase. The breakdown in
annual change is shown by WHO  region in Fig. 1. The greatest rate
of growth was seen in SEARO but the numbers of doses distributed
remain small for the region: 8.2 million in 2011. The lowest num-
ber of doses in 2011 was  distributed to AFRO (approximately 3.8
million), and the greatest number was  distributed in AMRO (255.6
million doses). EURO had the lowest rate of growth of all regions
with a 29% decrease between 2008 (which was a peak year at
approximately 144.2 million doses distributed) and 2011 (102.8
million doses distributed), for an overall growth of 14% between
2004 and 2011.
3.2.  IFPMA IVS dose distribution per 1000 population 2008–2011
Accounting for variations in country size, the data were ren-
dered comparable by calculating the ratio of IFPMA IVS doses
distributed per 1000 population, as shown in, for 2008 and 2011.
Data for AFRO, SEARO and EMRO are shown combined because they
only account for 3.7% of the more than 489 million doses distributed
in 2011. AFRO accounts for less than 1% of doses distributed (about
0.77% in 2011).
In  AMRO (Fig. 2), 21 out of 33 countries (64%) in the region
increased the per capita dose distribution between 2008 and 2011
A. Palache et al. / Vaccine 3
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hig. 1. Absolute numbers of doses of seasonal inﬂuenza vaccine distributed by WHO
egion between 2004 and 2011.
nd was signiﬁcantly different in 2011 (p = 0.008). Doses distributed
er 1000 population ranged from a high in the US of 476.6 in 2011
o a low of 0.69 in Haiti.In  EURO (Fig. 3), the highest per capita distribution in 2011
as observed in the UK and the Netherlands at 269.5 doses per
000 population each. However, a signiﬁcant number of countries
ave considerably reduced utilization rates since 2008. This change
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Fig. 2. Change between 2008 and 2011 in the number of doses of seasonal inﬂu2 (2014) 6369–6376 6371
was  signiﬁcant (p = 0.002) between 2008 and 2011. In 2008, the
Netherlands had a distribution rate of 452.5, but in 2011 had
decreased distribution by about 40%. Other countries like France
and Greece had similar decreases in distribution: 55% and 47%
respectively. In all, in EURO, 27/48 (56%) countries had lower dis-
tribution rates in 2011 than in 2008.
In WPRO (Fig. 4), the trend was  the opposite to the EU, with
the majority of countries 10/14 (71%) increasing doses distribu-
tion between 2008 and 2011 but the change was not signiﬁcant
(p = 0.11). The distribution rates ranged from a high of 460.6 per
1000 population in Japan to a low of 1.96 in Cambodia in 2011.
The rate in China increased from 8.58 in 2008 to 19.49 in 2011.
Surprisingly, Hong Kong was one of the few states in the region
to have decreased distribution between 2008 and 2011, dropping
from 180.1 to 138.1 per 1000 population, or a decrease of 23%.
In  EMRO, AFRO and SEARO (Fig. 5), doses were distributed
unevenly within the region with only 4 countries having distri-
butions of >70 doses per 1000 population (Mauritius, 185.5; DPR
Korea, 84.2; Lebanon 70.3; Qatar 70.9) in 2011. In AFRO, 12/20 (60%)
countries had distributions of <1 dose per 1000 population. Change
in all three regions combined was  not signiﬁcant between 2008 and
2011 (p = 0.11).
3.3. Countries with highest percent increase or decrease in IFPMA
IVS  dose distribution per 1000 population, between 2008 and 2011
Overall 65/115 (48%) countries increased doses distributed
per 1000 population between 2008 and 2011. However, there
was wide variance in the numbers of doses distributed between
countries for both increases and decreases in distribution. Thus,
some countries with very low distribution numbers in 2008 had
very high percent positive change in 2011 but still relatively low
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enza vaccine distributed per 1000 population in the WHO  AMRO region.
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istribution numbers. Montenegro, for instance, had a 1376%
hange in dose distribution between 2008 and 2011, but increased
oses distributed per 1000 population from 3.2 to only 47.5. And
ndia, which had a 452% increase in 2011, only moved from 0.2
o 1.1 doses distributed per 1000 population. Likewise, countries
ith high percent negative change in doses distributed per 1000
opulation may  have distributed relatively few doses in both 2008
nd 2011. Guatemala, for instance, had a 71% decrease in doses dis-
ributed in 2011 but numbers of doses fell from only 15 to 4.3 per
000 population.
There were 28/115 (24%) countries that distributed ≥159 doses
er 1000 population (the hurdle rate), in 2008, and an identi-
al number in 2011, although these were not always the same
ountries. We  compared the 9 countries with the highest propor-
ional increases in each of the hurdle groups to the 9 countries with
he greatest proportional decreases in each of the hurdle groups.
leven out of 18 countries (61%) with the greatest proportional
ecreases in the two hurdle groups, between 2008 and 2011, are
n EURO. By contrast the countries with the highest proportional
ncreases in the 2 hurdle groups are more evenly distributed by
egion: AMRO 5; EURO 4; WPRO 4; SEAR 3; and AFRO 2.
As  observed in the previous survey [8], percent rate of change
n distribution of doses per 1000 population is not correlated with
ountry income. Interviews with a selection of countries from each
roup will be conducted later to ascertain explanatory factors for
ncreased or decreased distribution rates.cine distributed per 1000 population in the EMRO, AFRO and SEARO regions.
4.  Discussion
4.1. Data quality
The  study’s results were compiled uniformly on a global basis
from a standardized source. The vaccine producers that manu-
facture the majority of the world’s inﬂuenza vaccines (IFPMA IVS
members) accounted for approximately 79% of the global seasonal
inﬂuenza vaccine production reported by a 2011 WHO  survey [10],
or 489 million doses out of 620 million doses, with the remainder
manufactured by non-IFPMA IVS members.
However, some limitations to the survey methods must be
noted. Some error may  have occurred due to inaccurate reporting
by distributors, but this error should be small. It is also recognized
that dose distribution is not synonymous with vaccination coverage
rates, but provides a reasonable proxy to assess vaccine utilization.
Also, increases in absolute numbers of doses distributed may in
some cases reﬂect changes in target populations (i.e., new target
groups), and not increased coverage.
4.2. Interpretation of quantitative resultsGlobal distribution of IFPMA IVS seasonal inﬂuenza vaccine
doses in 2011 represents an approximate 87% increase over abso-
lute number of doses distributed in 2004 (489.1 versus 261.7
million doses) as seen in Fig. 1, but only an approximate 12%
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ncrease over doses distributed in 2008 (489.1 versus 436.5 million
oses). Thus, while there is a positive trend in global distribu-
ion of doses, and a majority of countries (56%) have increased
oses distributed per 1000 population between 2008 and 2011, the
ate of growth has slowed considerably. In 2011, only 24% of 115
ountries had achieved or surpassed the hurdle rate of 159 doses
er 1000 population. Using vaccine dose distribution as a proxy
or vaccine coverage would therefore suggests that the majority
f countries have not achieved national or supranational targets
or inﬂuenza vaccination where they exist. Low coverage rates
annot be attributed to lack of vaccine supply as global manu-
acturing capacity for inﬂuenza vaccines has grown steadily but
emains underutilized with only about half the capacity being con-
umed annually [10]. Hence, many vulnerable patients are not
rotected against the potential serious implications of an inﬂuenza
nfection.
Furthermore, there are signiﬁcant regional disparities in dose
istribution. Increases in distributed doses have been predomi-
antly steady in all WHO  regions since 2004, except in EURO and
MRO where distributed doses have been declining since 2009.
FRO, SEARO and EMRO constitute 47% of the global population
ut account for only 14.1 million doses of the more than 489
illion IFPMA IVS doses (3.7%) distributed in 2011. And within
hese 3 regions, further inequities in distribution exist with only
 countries having distributions of >70 doses per 1000 population
nd the vast majority of countries having considerably lower per
apita distributions.
The  trends in the 3 regions where more than 96% of inﬂuenza
accine doses are distributed, AMRO, EURO and WPRO, vary by
egion. AMRO and WPRO have increased the per capita number of
oses distributed since 2008 as seen in Figs. 2 and 4. Surprisingly,
ong Kong was one of the few states in WPRO to have decreased
er capita distribution between 2008 and 2011, by 23%. EURO has
een a 29% decrease in numbers of doses distributed since 2008.
n all, 56% of countries in EURO had lower per capita distribution
ates in 2011 than in 2008 as seen in Fig. 3. The decline in distribu-
ion in EURO requires particular attention in light of the EU Council
ecommendations and its sharp contrasts with the trends in AMRO
nd WPRO.
However, it should be noted that the IFPMA IVS data may  not
ccurately represent dose distribution in some countries of some
HO regions, as non-IVS members may  supply the bulk of vaccine
n some large countries [10]. This is likely the case in India where
he IFPMA IVS doses distributed were 1.1 doses per 1000 population
n 2011. On the other hand, the IFPMA IVS data for EURO should
epresent the totality of doses distributed, as all doses are sourced
rom IFPMA IVS members [11].
As observed in the previous survey [8], percent rate of change
n distribution of doses per 1000 population is not correlated with
ountry income.
To  increase the relevance of this information, IFPMA IVS intends
o collect additional data on a range of vaccination uptake fac-
ors from a sub-group of countries to identify sharp increases and
ecreases in distribution rates and improves vaccination coverage
easures that can improve vaccination uptake. These data may
ontribute to a better understanding of the enablers of seasonal
nﬂuenza vaccination by region or by country.
Interviews will be conducted to assess whether factors such
s recommendations, reimbursement policies, and communica-
ion played a role in driving immunization in a selection of these
ountries, as suggested in the previous IFPMA IVS survey [8].
In  the US, where immunization recommendations originate
rom consultations with a broad array of stakeholders, including
edical/pediatric associations, NGOs, and the vaccine industry, it
s believed that community involvement may  act as a driver for vac-
ination coverage. Furthermore, pragmatic recommendations, such2 (2014) 6369–6376
as the Advisory Committee on Immunization Practices (ACIP) rec-
ommendation for routine use in all age groups, since 2010 [12], and
the department of Health and Human Services’ ambitious objec-
tives of 80%–90% coverage rate in various groups [13], are likely to
enhance VCR.
The  previous survey [8] showed little correlation between coun-
try wealth and dose distribution. We repeated the same analysis
for the current survey results and found that GNI did not correlate
with dose distribution. Few countries had important proportional
decreases in dose distribution/1000 pop. But surprisingly, 56% of
countries in EURO had negative dose distribution trends since the
last survey. The contraction in doses distributed in EURO can clearly
be noted in Fig. 1. In Europe, a lack of consensus to guide countries’
vaccination policy, a lack of political commitment to achieving
inﬂuenza vaccination targets, doubts about vaccine efﬁcacy and
effectiveness, safety concerns, or a lack of adherence to national
and supranational recommendation may  be factors that explain
this irrational negative trend. Recommendations for inﬂuenza vac-
cination may  also be less pragmatic in European countries than the
universal recommendation in the US, and this may  impact nega-
tively on VCRs. It should also be noted that a poor legacy from H1N1
vaccination in 2009, including poor communication to stakeholders
and lack of public conﬁdence, confusion between adverse events
(narcolepsy) from an adjuvanted pandemic vaccine [14–17] and
non-adjuvanted seasonal inﬂuenza vaccines may  be contributing
to the contraction of vaccine uptake in Europe.
In other countries, particularly in the AFRO, SEARO and EMRO
regions, insufﬁcient disease surveillance, such as is the case in
sub-Saharan Africa, may  mask the relevance of inﬂuenza dis-
ease and complicate ranking of this disease in the public health
hierarchy.
The attitude of health care professionals (HCPs) is also para-
doxical. In some settings as little as 40% of HCPs are themselves
immunized against inﬂuenza [18]. And yet, immunization of HCPs
could reduce mortality in patients by up to 50% [18]. For this rea-
son the World Medical Association (WMA)  has launched a global
inﬂuenza immunization campaign reminding physicians of their
ethical obligation to protect patients against inﬂuenza, and of the
importance of pre-exposure inﬂuenza immunization [18].
4.3.  The impact of inﬂuenza vaccination on chronic
non-communicable diseases (NCDs)
NCDs are the leading cause of death, accounting for about 63%
of deaths each year [19]. Major disease areas as deﬁned by WHO
include cardiovascular diseases, diabetes, cancers and chronic
respiratory conditions. About 80% of deaths from NCDs occur in
low- and middle-income countries. Common risk factors for these
four disease areas are tobacco use, unhealthy diet, physical inactiv-
ity and harmful use of alcohol. Yet, there are other factors, such as
seasonal inﬂuenza, which occur annually and can have detrimental
effects on people suffering from NCDs. Inﬂuenza-related serious ill-
ness and death occurs most frequently in groups such as the elderly
(65 years of age or older) and those with NCDs [2]. The effects of
inﬂuenza in these groups are more likely to extend beyond acute
infection, with a higher chance of hospitalizations and reduction
in independence and functioning [20]. Inﬂuenza vaccination can
reduce severe illness and complications by up to 60% and deaths
by 80% [21]. Prevention policies for NCDs should therefore encom-
pass additional measures, including annual immunization against
inﬂuenza.
As both developed and developing countries seek to maximize
their healthcare resources and manage an increasingly grow-
ing aging population, inﬂuenza prevention can be one practical
approach to manage the NCD burden and streamlining healthcare
system delivery. Inﬂuenza prevention can play an important role
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n the wider public health policy arena, by helping to meet tar-
ets for the reduction of inﬂuenza-related death in persons with
on-communicable conditions.
In  fact, vaccination of the elderly and disease prevention in the
ealth care setting are one of the ﬁve priority interventions laid
ut in the Healthy Aging Health Initiative for EURO. Its Strategy
nd Action Plan speciﬁcally refers to inﬂuenza vaccination as a
riority intervention [22]. The initiative recognizes that there is a
large overlap” between the NCD agenda and strategies for healthy
ging and that there is increasing evidence that the scope of pre-
entable diseases is linked to inadequate immunization coverage.
URO states are urged to ensure access to vaccination, particularly
or the elderly.
While  international efforts to raise VCR in particular for pediatric
accines have seen considerable gains in recent years (and received
onsiderable ﬁnancial support from donors), a tolerance for low
nﬂuenza VCR has meant that the WHA’s targets for inﬂuenza con-
rol have been largely missed [23]. Lower than desirable VCR also
as the potential to have negative consequences for pandemic
reparedness as insufﬁcient manufacturing capacity would mean
nsufﬁcient supply of a pandemic vaccine.
In the absence of frequent, accurate, and complete inﬂuenza
CR data, continued monitoring and evaluation of inﬂuenza vac-
ine dose distribution plays an important role in assessing progress
oward the WHA  targets for inﬂuenza VCR. Assessing the inﬂu-
nce factors for inﬂuenza VCR will be important for developing
dditional policies and practices to achieve VCR targets.
.  Conclusions
Seasonal inﬂuenza immunization imparts substantial health
nd economic beneﬁts, including an important reduction in
remature deaths and lost days of work, but systematic worldwide
ata have not been available to assist public health authori-
ies to review progress toward the 75% vaccination coverage
oals in target groups. The current IFPMA IVS dose distribution
urveys, covering 79% of inﬂuenza vaccines distributed globally
akes an important contribution to monitoring progress toward
CR goals.
Based on the current per capita distribution of inﬂuenza vac-
ine doses and recent reports on inﬂuenza VCR in the EU [24], most
ountries are considerably below 75% coverage in recommended
roups. The beneﬁts of inﬂuenza vaccination could therefore be sig-
iﬁcantly enhanced by raising the VCR in all WHO-recommended
arget groups. Recent reports from the UK and the US show that
nﬂuenza vaccination provides good value for money. In England,
nﬂuenza vaccination of the elderly and clinical risk groups was
ound to be cost-effective or very cost-effective [25]. In the US, uni-
ersal vaccination has been found to be cost saving compared to a
argeted vaccination program, saving $3.1 billion and 34,000QALYs
n an inﬂuenza season [26].
The current IFPMA IVS survey shows that while globally some
rogress has been made toward achieving WHO  vaccination cov-
rage targets, those gains are uneven across WHO  regions. While
he global distribution of seasonal inﬂuenza vaccines has grown
y almost 87% since 2004, the observed change between 2008
nd 2011 was only 12%. Since the beneﬁts or seasonal inﬂuenza
mmunization are widely documented and recognized [27,28],
t is worrying to note a decline in dose distribution, partic-
larly in 56% of countries of EURO where on the whole the
ose distribution per population is higher than in other WHO
egions.Partridge et al. [10] noted that only about half of the global vac-
ine capacity for a northern hemisphere seasonal inﬂuenza vaccine
as being utilized in 2011, and even less for a southern hemi-
phere vaccine. This may  have potentially adverse consequences on
[2 (2014) 6369–6376 6375
pandemic preparedness as logistically manufacturing and country
capacity go untested. Production capacity may  also shrink to better
ﬁt with annual uptake further compromising pandemic prepared-
ness.
Given the economic beneﬁts of seasonal inﬂuenza immuniza-
tion [5,25,26] there should be a renewed focus on the burden
imposed by inﬂuenza and the policies required to limit its effect
on public health. HCPs should serve as role models and act in the
best interest of their patients by preventing outbreaks through pre-
exposure inﬂuenza immunization.
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